The trajectory of copyright's flagship drug presents a complex case for investors in the pharmaceutical sector. While initially a phenomenal success, producing vast sums, the patent expiration and the subsequent flood of off-brand alternatives have considerably impacted earnings. This poses questions about the long-term viability of related medi… Read More